The first accurate characterization of CTCs was reported in 1998 by Racila et al. In this work, the authors detected and isolated CTCs in the blood of patients with breast and prostate cancer using magnetic ferrofluids coupled with an epithelial cell adhesion molecule (EpCAM) antibody followed by cell cytometry [106]. Here, EPCAM is linked to prostate carcinoma.